Cargando…
Auranofin, at clinically achievable dose, protects mice and prevents recurrence from Clostridioides difficile infection
Clostridioides difficile is the leading cause of nosocomial infections and a worldwide urgent public health threat. Without doubt, there is an urgent need for new effective anticlostridial agents due to the increasing incidence and severity of C. difficile infection (CDI). The aim of the present stu...
Autores principales: | Abutaleb, Nader S., Seleem, Mohamed N. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7206065/ https://www.ncbi.nlm.nih.gov/pubmed/32382070 http://dx.doi.org/10.1038/s41598-020-64882-9 |
Ejemplares similares
-
In vivo efficacy of auranofin in a hamster model of Clostridioides difficile infection
por: Abutaleb, Nader S., et al.
Publicado: (2021) -
Investigating auranofin for the treatment of infected diabetic pressure ulcers in mice and dermal toxicity in pigs
por: Mohammad, Haroon, et al.
Publicado: (2021) -
Auranofin Rapidly Eradicates Methicillin-resistant Staphylococcus aureus (MRSA) in an Infected Pressure Ulcer Mouse Model
por: Mohammad, Haroon, et al.
Publicado: (2020) -
Repurposing auranofin as an intestinal decolonizing agent for vancomycin-resistant enterococci
por: AbdelKhalek, Ahmed, et al.
Publicado: (2018) -
Auranofin exerts antibacterial activity against Neisseria gonorrhoeae in a female mouse model of genital tract infection
por: Elhassanny, Ahmed E. M., et al.
Publicado: (2022)